Macquarie Group
AVXL icon

Macquarie Group’s Anavex Life Sciences AVXL Stock Holding History

Macquarie Group’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,097
Closed -$11.6K – 2339
2022
Q2 		$11K Hold
1,097
– – ﹤0.01% 2422
2022
Q1 		$14K Hold
1,097
– – ﹤0.01% 2458
2021
Q4 		$19K Hold
1,097
– – ﹤0.01% 2404
2021
Q3 		$20K Hold
1,097
– – ﹤0.01% 2454
2021
Q2 		$25K Buy
+1,097
New +$16.2K ﹤0.01% 2314

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Macquarie Group's AVXL Position: Q3 2022 in Review

Macquarie Group sold out of Anavex Life Sciences (AVXL) in Q3 2022, closing a stake of 1,097 shares — an estimated $11.6K sold.

Macquarie Group first reported a position in AVXL in Q2 2021 and held it in 5 quarters. The position peaked at $25K in Q2 2021. 147 funds tracked by Wall St. Rank hold AVXL as of Q3 2022.

  • Macquarie Group reported no remaining Anavex Life Sciences position as of Q3 2022 after selling out during the quarter.
  • Macquarie Group sold 1,097 Anavex Life Sciences shares in Q3 2022, an estimated $11.6K.
  • Macquarie Group first reported a position in Anavex Life Sciences in Q2 2021 and held it in 5 quarters.
  • Macquarie Group's Anavex Life Sciences position peaked at $25K in Q2 2021.
  • 147 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.